1-10 of 10
Farheen Mir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

Farheen Mir, Anna Robinson, Mark Edward Ethell, Michael Potter, Emma Nicholson, Chloe Anthias, Sandra Easdale, Carlos Gonzalez-Arias, Amit Sud, Claire E. Dearden, Ian Chau, David Cunningham, Dima El-Sharkawi, Bhupinder Sharma, Sunil Iyengar
Journal: Blood
Blood (2022) 140 (Supplement 1): 9366–9367.
https://doi.org/10.1182/blood-2022-166198
Published: 2022
Journal Articles

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Clinical Trials & Observations
Christopher R. Bolen, Federico Mattiello, Michael Herold, Wolfgang Hiddemann, Sarah Huet, Wolfram Klapper, Robert Marcus, Farheen Mir, Gilles Salles, Oliver Weigert, Tina Nielsen, Mikkel Z. Oestergaard, Jeffrey M. Venstrom
Journal: Blood
Blood (2021) 137 (19): 2704–2707.
https://doi.org/10.1182/blood.2020008119
Published: 2021
Includes: Supplemental data
Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Clinical Trials & Observations
Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Robin Gasiorowski, Richard Greil, Árpád Illés, Nathalie A. Johnson, Jean-François Larouche, Pieternella J. Lugtenburg, Caterina Patti, Gilles A. Salles, Marek Trněný, Sven de Vos, Farheen Mir, Divya Samineni, Su Y. Kim, Yanwen Jiang, Elizabeth Punnoose, Arijit Sinha, Emma Clark, Nathalie Spielewoy, Kathryn Humphrey, Alexandra Bazeos, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 137 (5): 600–609.
https://doi.org/10.1182/blood.2020006578
Published: 2021
Includes: Supplemental data
Journal Articles

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Clinical Trials & Observations Brief Report
Farheen Mir, Sally F. Barrington, Helen Brown, Tina Nielsen, Deniz Sahin, Michel Meignan, Judith Trotman
Journal: Blood
Blood (2020) 135 (15): 1214–1218.
https://doi.org/10.1182/blood.2019001091
Published: 2020
Includes: Supplemental data
Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5268.
https://doi.org/10.1182/blood-2019-123466
Published: 2019
Journal Articles

Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study

Farheen Mir, MBBS, Sally F Barrington, Michel Meignan, Helen Brown, Tina Nielsen, Deniz Sahin, Judith Trotman
Journal: Blood
Blood (2018) 132 (Supplement 1): 4160.
https://doi.org/10.1182/blood-2018-99-116686
Published: 2018
Journal Articles

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Franck Morschhauser, Pierre Feugier, Ian W. Flinn, MD PhD, Robin E Gasiorowski, Richard Greil, MD, Árpád Illés, Nathalie A Johnson, MDPhD, Jean-Francois Larouche, Pieternella J Lugtenburg, Caterina Patti, Gilles Salles, MD PhD, Marek Trněný, Sven de Vos, Farheen Mir, MBBS, Martin Kornacker, Elizabeth A Punnoose, Divya Samineni, Edith Szafer-Glusman, Adam Petrich, Arijit Sinha, Mehrdad Mobasher, MD MPH, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 782.
https://doi.org/10.1182/blood-2018-99-118519
Published: 2018
Journal Articles

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Jonathan C Strefford, Malgorzata Nowicka, Chantal Hargreaves, Chisako Iriyama, Kate V Latham, Rosalind Ganderton, Helen Parker, Kathleen N Potter, Andrea Knapp, Farheen Mir, Matthew JJ Rose-Zerilli, Cathy Burton, Wolfgang Hiddemann, Wolfram Klapper, MD, Laurie H Sehn, MD MPH, Umberto Vitolo, Maurizio Martelli, Marek Trněný, Andrew Davies, Mark C Cragg, Mikkel Z Oestergaard
Journal: Blood
Blood (2018) 132 (Supplement 1): 4109.
https://doi.org/10.1182/blood-2018-99-116750
Published: 2018
Journal Articles

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Farheen Mir, MBBS, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F. Seymour, MBBS, PhD, Christopher R Bolen, Andrea Knapp, Aino Launonen, Federico Mattiello, Tina Nielsen, Mikkel Z Oestergaard, Michael Wenger, Carla Casulo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2872.
https://doi.org/10.1182/blood-2018-99-114620
Published: 2018
Journal Articles

Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma

Charlotte Wilding, BSc, MBChB, Farheen Mir, MBBS, Indu Mitra, Bhupinder Sharma, Larissa Sena, Andrew Wotherspoon, David Cunningham, MD FRCP, Ian Chau, MD, Claire E. Dearden, MD FRCP, FRCPath, Kabir Mohammed, Sunil Iyengar
Journal: Blood
Blood (2017) 130 (Supplement 1): 2786.
https://doi.org/10.1182/blood.V130.Suppl_1.2786.2786
Published: 2017